Immunotherapy plus chemotherapy after lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy after lung cancer surgery can help stop the cancer from coming back. It is for people with non-small cell lung cancer that has not spread to the brain and does not have certain genetic changes (EGFR/ALK mutations).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and were diagnosed with non-small cell lung cancer (NSCLC).
- You had surgery to remove the entire tumor, and it was confirmed that no cancer cells were left at the edges (called R0 resection).
- Your cancer is at stage II, IIIA, or IIIB(N2), meaning it has spread to lymph nodes in the chest but not to distant organs.
- Your tumor does not have EGFR or ALK mutations (your doctor will have tested this).
- You have not had any other cancer treatments (like chemotherapy or radiation) for this lung cancer before—only surgery.
- You are in generally good health (able to do daily activities, no major heart, liver, or kidney problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an experimental drug (SYS6010) together with an immunotherapy (a type of treatment that helps your immune system fight cancer) after surgery can lower the chance of cancer coming back. It's for people with non-small cell lung cancer that was completely removed but didn't respond very well to surgery alone.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink non-small cell lung cancer and improve treatment success. The drugs are toripalimab and sacituzumab tirumotecan, which are given as intravenous infusions.
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
This trial tests whether giving an immunotherapy drug called toripalimab together with chemotherapy after lung cancer surgery can help prevent small cell lung cancer from coming back. It is for people who had surgery to remove lung cancer and were found to have small cell lung cancer in the removed tissue.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.